The Clinical Significance of HLA Compatibility Scores in Lung Transplantation
Transplant International · 2025
DOI: 10.3389/ti.2024.13484 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Transplant International, 2025. Verfasst von Liesbeth Daniëls und 8 weiteren Autor:innen. Beteiligte Einrichtung: Histocompatibility Laboratory (HLA), Clinical Biology, CHU UCL Namur Site Godinne, Namur, Belgium. Hauptthemen laut MEDLINE: Lung Transplantation, HLA Antigens. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung transplantation is a life-saving therapeutic option for many chronic end-stage pulmonary diseases, but long-term survival may be limited by rejection of the transplanted organ. Since HLA disparity between donor and recipient plays a major role in rejection, we performed a single center, retrospective observational cohort analysis in our lung transplant cohort (n = 128) in which we calculated HLA compatibility scores for B-cell epitopes (HLAMatchmaker, HLA-EMMA), T-cell epitopes (PIRCHE-II) and missing self-induced NK cell activation (KIR Ligand Calculator). Adjusted Cox proportional hazards model was used to investigate the association between mismatched scores and time to development of donor-specific antibodies (DSA) post-transplant, time to first biopsy-proven acute rejection episode, freedom from CLAD, graft survival and overall survival. For time to first DSA, HLA-EMMA DQB1 scores and PIRCHE-II DQB1 scores were significantly associated with more rapidly developing anti-HLA-DQ antibodies. HLA-EMMA DQB1 score was significantly associated with worse survival. KIR ligand Host-versus-Graft (HvG) mismatches was significantly associated with worse graft survival (CLAD or death) and shorter time to first biopsy-proven rejection when 2 mismatches were present. We demonstrated that HLA-DQB1 compatibility scores and KIR ligand HvG 2 mismatches may allow for identification of recipients at risk of poor long-term outcomes after lung transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Histocompatibility Laboratory (HLA), Clinical Biology, CHU UCL Namur Site Godinne, Namur, Belgium.
- Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
- Department of Chronic Diseases, Metabolism and Ageing, Laboratory for Respiratory Diseases and Thoracic Surgery, Faculty of Medicine, KU Leuven, Leuven, Belgium.
- Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Brussels, Belgium.
- Department of Microbiology, Immunology and Transplantation, Faculty of Medicine, KU Leuven, Leuven, Belgium.
- Eurotransplant and Eurotransplant Reference Laboratory, Department of Immunology, Leiden University Medical Center (LUMC), Leiden, Netherlands.
Zitieren
APA
Daniëls, L., Beeckmans, H., Zajacova, A., Kerckhof, P., Bos, S., Naesens, M., Vanaudenaerde, B., Claas, F., & Vos, R. (2025). The Clinical Significance of HLA Compatibility Scores in Lung Transplantation. Transplant International. https://doi.org/10.3389/ti.2024.13484
Vancouver
Daniëls L, Beeckmans H, Zajacova A, Kerckhof P, Bos S, Naesens M, et al. The Clinical Significance of HLA Compatibility Scores in Lung Transplantation. Transplant International. 2025. doi:10.3389/ti.2024.13484
BibTeX
@article{Danils2025,
author = {Daniëls, Liesbeth and Beeckmans, Hanne and Zajacova, Andrea and Kerckhof, Pieterjan and Bos, Saskia and Naesens, Maarten and Vanaudenaerde, Bart and Claas, Frans and Vos, Robin},
title = {The Clinical Significance of HLA Compatibility Scores in Lung Transplantation},
journal = {Transplant International},
year = {2025},
doi = {10.3389/ti.2024.13484}
}
EUVIMED